Connect Biopharma Presents Data Supporting Rademikibart at EAACI 2025
Connect Biopharma presented clinical data on rademikibart, its investigational IL-4Rα antibody for asthma and COPD, at the 2025 EAACI...
BEAM-101 Shows Strong SCD Results in Phase 1/2 Trial
Beam Therapeutics announced updated safety and efficacy data from its BEACON Phase 1/2 trial of BEAM-101, a base editing...
Biomea Fusion at EHA 2025: Covalent FLT3 Inhibitor Shows Promising Data
Biomea Fusion released preliminary Phase I data from its COVALENT-103 trial of BMF-500 in relapsed or refractory acute leukemia...
Briquilimab Shows Promise in Chronic Urticaria Study
Jasper Therapeutics announced positive Phase 1b/2a trial results for briquilimab, a subcutaneous antibody targeting KIT (CD117), in patients with...
Intellia: Positive 3-Year Lonvo-Z Data in HAE Trial
Intellia Therapeutics announced positive three-year follow-up data from the Phase 1 portion of its ongoing Phase 1/2 study of...
Elkedonia Secures €11M to Develop Neuropsychiatric Therapeutics
Elkedonia, a Franco-Belgian startup launched by Argobio and based on research from Sorbonne University, secured €11.25 million in seed...
Zoryve® Cream 0.05% in Infants with Atopic Dermatitis
Arcutis Biotherapeutics has initiated a Phase 2 trial, INTEGUMENT-INFANT, to assess the safety and tolerability of its investigational ZORYVE...
FDA Clears Monte Rosa’s MRT-8102 IND for Inflammatory Diseases
Monte Rosa Therapeutics has received FDA approval to begin clinical trials for MRT-8102, a novel molecular glue degrader (MGD)...
MP0533 Shows Promise in AML Trial
Molecular Partners released positive Phase 1/2a trial data for MP0533, a tetraspecific T-cell engager targeting relapsed/refractory acute myeloid leukemia...
Polypid’s SHIELD II Trial Delivers Transformative Results
PolyPid Ltd. announced positive topline results from its Phase 3 SHIELD II trial of D-PLEX100, demonstrating a statistically significant...